SCHEMBL4477862

SCHEMBL4477862

O=S(=O)(NCc1ccc(Cl)cc1Cl)c1ccc2c(O)cccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
NPC1 O15118 1/20 0.54
MAPT P10636 1/20 0.54
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.46
CYP19A1 P11511 2/20 0.44
ERCC1 P07992 1/20 0.43
ERCC4 Q92889 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
MAPK1 P28482 1/20 0.42
SCN9A Q15858 1/20 0.41
GNRHR P30968 1/20 0.41
PYGL P06737 1/20 0.40
TUBB P07437 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478333 0.82 ALDH1A1 (0.50) ALDH1A1NPC1MAPTCYP1A2CYP3A4
SCHEMBL4478162 0.81 CA2 (0.56) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4488539 0.80 MCL1 (0.49) ALDH1A1NPC1MAPTCYP1A2CYP3A4
SCHEMBL4472784 0.78 CYP19A1 (0.62) ALDH1A1CYP1A2CYP3A4CYP19A1MAPK1
SCHEMBL14434546 0.75 ALDH1A1 (0.57) ALDH1A1NPC1MAPTMEN1KMT2A
SCHEMBL14434548 0.75 MAPT (0.64) ALDH1A1NPC1MAPTCYP1A2CYP3A4
SCHEMBL6066379 0.75 AKR1C3 (0.61) ALDH1A1NPC1MAPTCYP2C19MEN1
SCHEMBL4471169 0.74 LMNA (0.50) MAPTCYP1A2CYP2C9MEN1KMT2A
SCHEMBL4478227 0.74 CYP19A1 (0.61) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL27935857 0.73 ALDH1A1 (0.73) ALDH1A1NPC1MAPTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 ALDH1A1 1461/4885NPC1 2545/4885MAPT 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.